Systematic management programme for mestizo pulmonary diseases caused by erythalamus

The SLE is a self-immunised disease that can be drained to multiple organ systems, in which IMTS (ILD) is one of the more serious complications, as described below in the Integrated Management Programme for such patients.

I. Disease surveillance and assessment

Comprehensive and regular physical examinations, including lung function tests (e.g., pulmonary activity, dispersive function), chest high resolution CT (HRCT) scans, self-antibody tests (e.g., anti-nucleus, double-chain DNA, antibodies, etc.) and laboratory examinations such as blood routines, liver and kidney function. Through these examinations, doctors can assess the activity of the disease, the progress of pulmonary pathologies and the side effects of drugs, so that treatment programmes can be adjusted in a timely manner.

II. Drug treatment and management

1. Immunosuppressants: Depending on the severity of the condition, sugar-coated hormones (e.g., Penistone) may be used in combination with other immunosuppressants (e.g., cyclophosphate, mecrophenol, etc.) to control SLE activities and reduce pneumonia. However, adverse effects of drugs, such as increased risk of infection, bone marrow inhibition and damage to liver and kidney function, need to be closely monitored.

Anti-fibrosis drugs: For patients with pulmonary fibrosis, the use of anti-fibrosis drugs (e.g. fennione, Nidanib) may be considered to slow down the reduction of lung function. In this use, attention is paid to the side effects of gastrointestinal discomfort and rashes, and the efficacy of treatment is regularly assessed.

III. Lifestyle adjustments

1. Stop smoking: smoking increases lung damage and patients must quit smoking and avoid inhalation of second-hand smoke.

2. Sports and rehabilitation: During a stable period of illness, aerobics (e.g. walking, Tai Chi Fist) are properly carried out, contributing to the improvement of CPR function and physical endurance. At the same time, respiratory rehabilitation training, such as deep breathing exercises, condensed lips, etc., may be arranged according to the patient ‘ s condition, to improve respiratory muscle strength and respiratory efficiency.

3. Nutritional support: ensure a balanced diet with sufficient proteins (e.g., skinny meat, fish, beans), vitamins (fresh vegetables and fruits) and minerals to maintain normal body metabolic and immune functions. For patients with difficulties in swallowing or with gastrointestinal symptoms, dietary adjustments or nutritional supplements may be required.

IV. Psychological support and health education

1. Psychological care: SLE Combined ILD patients are vulnerable to psychological problems such as anxiety and depression due to the chronicity of the disease, the complexity of the treatment and the fear of its prognosis. Medical personnel should provide psychological support and, if necessary, psychological counselling.

2. Patient education: Provides patients and their families with detailed information about the disease, including its causes, symptoms, treatment methods, drug side effects and daily care. To educate patients about the importance of regular drug use, regular review, and to enhance self-management and treatment compliance.

Prevention and response to complications

Close attention is paid to the occurrence of complications such as infections (e.g. lung infection, urinary tract infections), pulmonary artery high pressure, respiratory failure, etc. Strengthen preventive measures such as influenza vaccination, pneumococcal vaccination, etc. In the event of complications, appropriate treatment, such as anti-infection treatment, oxygen therapy, mechanical ventilation, etc., should be provided in time to reduce mortality.

The above-mentioned multidimensional and integrated management can improve the quality of life of people with mestizo pulmonary diseases caused by systematic red erythalamus, slow the progress of the disease and improve the expectations.